The secretive system for vetting cancer drug use needs an urgent overhaul
(By Ed Silverman for STAT) In the complicated world of medicine and money, the federal government relies on a handful
Read More
Part D/Prescription Drugs
EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog
(By Sydney Lupkin for Kaiser Health News) Consumers and Congress members pushing for cheaper alternatives to the EpiPen and other
Read MoreHidden network of kratom devotees tries to keep the supplement safe — and legal
(By Eric Boodman for STAT) When money is scarce, Margo Burton and her husband will go without cigarettes. Sometimes her
Read MoreAnyone see the rebates? Lawmakers accuse Mylan of underpaying Medicaid for EpiPen
(By Ed Silverman for STAT) Did Mylan Pharmaceuticals misclassify EpiPen to avoid paying higher Medicaid rebates? Continue reading article here…..
Read MoreHurdles abound in race to bring customized cancer treatments to masses
(By Meghana Keshavan for STAT) The idea is tantalizing: Reengineer a patient’s own immune cells to attack the cancer that’s
Read MoreAn Even Deadlier Opioid, Carfentanil, Is Hitting The Streets
(By Jennifer Ludden for NPR) A powerful drug that’s normally used to tranquilize elephants is being blamed for a record
Read MoreTest Of Experimental Alzheimer’s Drug Finds Progress Against Brain Plaques
(By Jon Hamilton for NPR) An experimental drug dramatically reduced the toxic plaques found in the brains of patients with
Read MoreFDA Boosts Warning On Danger Of Combining Opioids And Anxiety Meds
(By Joe Neel for NPR) The Food and Drug Administration is warning that patients and doctors should more fully understand
Read MoreMylan’s Generic EpiPen — A Price Break Or Marketing Maneuver?
(By Julie Appleby for Kaiser Health News) Following weeks of criticism over dramatic price increases on its EpiPen, Mylan said
Read MoreFDA to hold long-awaited meeting to review off-label marketing
(By Ed Silverman for STAT) After years of anticipation, the US Food and Drug Administration will hold a public, two-day
Read More